Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury
NCT06840899Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in urinary incontinence (UI) and Neurogenic Lower Urinary Tract Dysfunction (NLUTD), sponsored by University of Wisconsin–Madison. Primary endpoints: Adherence to CBD (Epidiolex) regimen at 90 days, Completion of 72-hour voiding diary at 90 days and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
urinary incontinence (UI)Neurogenic Lower Urinary Tract Dysfunction (NLUTD)
Beyond the preview
Go deeper on NCT06840899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840899.